(Q39583133)

13 September 2017

title

The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy (English)

1 reference

13 September 2017

S J Weir

1

1 reference

13 September 2017

L Patton

2

1 reference

13 September 2017

K Castle

3

1 reference

13 September 2017

L Rajewski

4

1 reference

13 September 2017

J Kasper

5

1 reference

13 September 2017

A D Schimmer

6

1 reference

13 September 2017

language of work or name

1 reference

24 August 2010

1 reference

Journal of Clinical Pharmacy and Therapeutics

13 September 2017

published in

1 reference

13 September 2017

volume

36

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

128-134

1 reference

Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic derm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

Modeling the initiation and progression of human acute leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2010.01172.X

10.1111/J.1365-2710.2010.01172.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference